Press Room

Earlier today, cancer survivors, medical professionals and patient advocates from across Delaware convened in Dover at Legislative Hall as a part of ‘Delaware Advocacy Day.’ The main focus of Advocacy Day, which was hosted by the American Cancer Society Cancer Action Network (ACS CAN) and the Alzheimer’s Association (ALZ), was for volunteers to connect directly with legislators and ask for their support of Senate Bill 120, a bipartisan proposal to improve Delawareans’ access to biomarker testing.

JACKSON, Miss. –  The Mississippi Senate passed “Jill’s Law” House Bill 565 Wednesday, paving the way for increased access to biomarker testing for Mississippians with state-regulated he

JACKSON, Miss. – The Mississippi Senate passed Senate Bill 2694 Wednesday, February 11, paving the way for increased access to biomarker testing for patients across the Magnolia State.

Más de una docena de voluntarios de ACS CAN se reunieron en el Capitolio de Nueva York para instar a los legisladores a que preserven el acceso a las pruebas de biomarcadores, una prioridad para más de 100 organizaciones.

JACKSON, Miss. – Dozens of cancer patients, survivors, caregivers and advocates will come from across Mississippi to the State Capitol on Wednesday, February 4 for the American Cancer Society Cancer Action Network’s (ACS CAN) annual

NASHVILLE, Tenn.

JACKSON, Miss. –  The Mississippi House passed House Bill 565 Wednesday, paving the way for increased access to biomarker testing for patients across the Magnolia State.

Ahead of Mills' State of the State address, ACS CAN Calls Attention to Medicaid, Biomarker Testing and Medical Debt

With the 2026 legislative session now underway in Hawai’i, the American Cancer Society Cancer Action Network (ACS CAN) is leading efforts to work with lawmakers on several initiatives which include defending Medicaid and expanding access to screenings for colorectal cancer for the state’s most vu

 A new ACS CAN study released in the Journal of the American Medical Association (JAMA) finds many patients aren’t made aware of the importance of pharmacogenomic (PGx) testing. A form of biomarker testing, PGx testing examines how variations in a patient’s inherited genes may impact how they respond to different drugs and can improve the effectiveness of treatment and reduce the risk of adverse drug reactions.